Martin Smoragiewicz - Concepedia

Author

Martin Smoragiewicz

Princess Margaret Cancer Centre ORCID

Also Known As

Lillian L. Siu, M. Smoragiewicz, Martin Smoragiewicz, Nadeem Riaz, Smoragiewicz, Martin

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre BC Cancer Agency Sunnybrook Health Science Centre University of Calgary Queen Elizabeth II Health Sciences Centre

About

Martin Smoragiewicz is an author at Princess Margaret Cancer Centre specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	678
2	Pathology	3	3	60
3	Health Sciences	2	2	22
4	Immunology	1	1	147
5	Neurology	1	1	35

Martin Smoragiewicz

Publications

995

Citations

H-Index

Page 1

	Year	Citations
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Jenny J. Ko, Wanling Xie, Nils Kroeger, The Lancet Oncology First-line Targeted TherapyUrologyPopulation-based StudyGenitourinary CancerMedicine	2015	364
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response Daniele Biasci, Martin Smoragiewicz, Claire M. Connell, Proceedings of the National Academy of Sciences	2020	241
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy Arnoud J. Templeton, Jennifer J. Knox, Xun Lin, European Urology UrologyCancer ImmunosurveillanceGenitourinary CancerMedicineImmunology	2016	147
Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies Nils Kroeger, Allan J. Pantuck, J. Connor Wells, European Urology UrologyGenitourinary CancerMedicineLymph Node MetastasesSurvival Outcome	2014	43
Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Marina D. Kaymakcalan, Wanling Xie, Laurence Albigès, Cancer	2015	35
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study Sarah Lapointe, Warren Mason, Mary MacNeil, Investigational New Drugs Glioblastoma MultiformeDual Mtorc1/2 InhibitorMedicinePharmacologyPharmacotherapy	2019	35
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226 Rosalyn A. Juergens, Desirée Hao, Peter Ellis, Lung Cancer Phase Ib StudyMedicinePharmacologyPathologyAdvanced Solid Tumours	2020	28
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response Daniele Biasci, Martin Smoragiewicz, Claire M. Connell,	2020	21
Neutropenia and Relative Dose Intensity on Adjuvant FOLFOX Chemotherapy Are Not Associated with Survival for Resected Colon Cancer Martin Smoragiewicz, Khodadad Rasool Javaheri, Yaling Yin, Journal of Gastrointestinal Cancer Resected Colon CancerSurgical OncologyOncologyGastrointestinal OncologyColorectal Cancer	2014	20
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) Sébastien J. Hotte, Eric Winquist, K.N. Chi, Annals of Oncology UrologyCctg Ind 232Genitourinary CancerMedicinePhase Ii Study	2019	19

Page 1